EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement

George A Mensah, Natalie Arnold, Sumanth D Prabhu, Paul M Ridker, Francine K Welty

JACC · 2026-03 · 87 (11) · 1381-1404

DOI: 10.1016/j.jacc.2025.08.047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JACC, 2026-03. Verfasst von George A Mensah und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Cardiology, Cardiovascular Diseases, Inflammation. Die Arbeit wurde bisher 218-mal zitiert (Crossref) und nennt 127 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The crucial role of inflammation in the pathogenesis and clinical outcomes of cardiovascular disease (CVD) has recently gained increased attention. In particular, residual inflammation, measured with high-sensitivity C-reactive protein (hsCRP) remains strongly predictive of recurrent events, even in statin-treated patients. Similarly, elevated hsCRP in apparently healthy individuals identifies a higher-risk group in whom statin therapy significantly reduces the risk of first major CVD events even if LDL-cholesterol is normal. This report provides an updated understanding of the role of chronic, low-grade inflammation in CVD and highlights new seminal research findings, especially in atherosclerosis, myocardial infarction, heart failure, and pericarditis. Consensus recommendations are summarized for screening, evaluation, and CVD risk assessment; inflammatory biomarkers in cardiovascular imaging; inflammation inhibition in behavioral and lifestyle risks; and anti-inflammatory approaches in primary and secondary prevention as well as in heart failure and other CVDs. This report also addresses current challenges and future opportunities. For example, it cautions that not all trials of anti-inflammatory therapy in secondary prevention have been successful and such trial evidence is needed before broad recommendations for other agents can be made. Additionally, in successful trials, the interplay between inflammation and key physiological systems often remains incompletely examined. Another promising area of research is the role that novel special pro-resolving bioactive lipid molecules play in promoting the resolution of inflammation and CVD risk reduction. In aggregate, the evidence linking inflammation with atherosclerotic CVD is no longer exploratory but is compelling and clinically actionable. The time for taking action has now arrived.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiologyCardiovascular DiseasesInflammationHumansBiomarkersC-Reactive ProteinHydroxymethylglutaryl-CoA Reductase InhibitorsRisk AssessmentSocieties, MedicalUnited States

Stichwörter der Autor:innen

ACC Scientific Statementcardiovascular diseasehigh-sensitivity C-reactive proteininflammationomega-3 fatty acidsprevention

Substanzen

BiomarkersC-Reactive ProteinHydroxymethylglutaryl-CoA Reductase Inhibitors

Zitieren

APA

Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2026). Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. JACC, 87(11), 1381-1404. https://doi.org/10.1016/j.jacc.2025.08.047

Vancouver

Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. JACC. 2026;87(11):1381-1404. doi:10.1016/j.jacc.2025.08.047

BibTeX
@article{Mensah2026,
  author = {Mensah, George A and Arnold, Natalie and Prabhu, Sumanth D and Ridker, Paul M and Welty, Francine K},
  title = {Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement},
  journal = {JACC},
  year = {2026},
  volume = {87},
  number = {11},
  pages = {1381--1404},
  doi = {10.1016/j.jacc.2025.08.047}
}
Kostenlos starten →